Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3

Executive Summary

MGI Pharma expects to file an NDA for Saforis (l-glutamine oral suspension) for the treatment of oral mucositis based on the results of one Phase III trial and supportive earlier-phase trials

You may also be interested in...

MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration

MGI will highlight the efficacy profile of its myelodysplastic syndromes therapy Dacogen when detailing decitabine to oncologists

Aloxi Sees Share Gains, Volume Drop In First Month Under Medicare ASP

MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class

Amgen Kepivance To Launch In January; Additional Mucositis Trials Underway

Amgen will launch the oral mucositis treatment Kepivance (palifermin) in late January following FDA approval Dec. 15





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts